Last reviewed · How we verify
CardiolRx
CardiolRx is a cardiac-regenerative therapy designed to repair and restore heart function following myocardial injury.
CardiolRx is a cardiac-regenerative therapy designed to repair and restore heart function following myocardial injury. Used for Acute myocardial infarction with reduced ejection fraction, Heart failure with reduced ejection fraction.
At a glance
| Generic name | CardiolRx |
|---|---|
| Also known as | Cannabidiol, Pharmaceutically produced Cannabidiol, Pharmaceutically produced cannabidiol |
| Sponsor | Cardiol Therapeutics Inc. |
| Drug class | Exosome therapy |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
CardiolRx utilizes exosome-based technology derived from mesenchymal stem cells to deliver therapeutic cargo that promotes cardiac tissue repair, reduces inflammation, and improves ventricular function. The mechanism involves modulation of the cardiac microenvironment to support regeneration and reduce fibrosis following acute myocardial infarction or heart failure.
Approved indications
- Acute myocardial infarction with reduced ejection fraction
- Heart failure with reduced ejection fraction
Common side effects
- Infusion-related reactions
- Arrhythmias
- Hypotension
Key clinical trials
- CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3) (PHASE3)
- Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot) (PHASE2)
- Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors (PHASE2, PHASE3)
- Impact of CardiolRx on Myocardial Recovery in Patients With Acute Myocarditis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CardiolRx CI brief — competitive landscape report
- CardiolRx updates RSS · CI watch RSS
- Cardiol Therapeutics Inc. portfolio CI